Seqirus UK Limited, a prominent player in the biopharmaceutical industry, is headquartered in Great Britain. Established as a subsidiary of CSL Limited, Seqirus focuses on the development and distribution of innovative vaccines and immunotherapy solutions. With a strong presence in Europe and North America, the company has made significant strides since its founding in 2015, particularly in the field of influenza vaccines.
Seqirus is renowned for its unique product offerings, including the adjuvanted flu vaccine, which enhances immune response, setting it apart in a competitive market. The company has achieved notable milestones, such as being one of the largest influenza vaccine manufacturers globally. With a commitment to public health and a robust pipeline of vaccine candidates, Seqirus continues to solidify its position as a leader in the vaccine industry.
+7 vs industry average
Seqirus UK Limited’s score of 35 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Seqirus UK Limited?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Real Estate Services has above-average carbon intensity
Industry performance
The Real Estate Services industry has reduced its overall emissions by 42% since 2019
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Seqirus UK Limited's reported carbon emissions
In 2025, Seqirus UK Limited reported total carbon emissions of approximately 286 million kg CO2e, comprising 135 million kg CO2e from Scope 1 and 151 million kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data, indicating potential gaps in their reporting.
Seqirus UK Limited is a current subsidiary of CSL Limited, which may influence its climate commitments and reporting practices. However, there are no specific reduction targets or initiatives outlined in their current data, and no climate pledges have been made public.
The company’s emissions data reflects a significant reliance on direct and indirect emissions from its operations, highlighting the importance of addressing these areas in future sustainability strategies. As part of the broader industry context, Seqirus UK Limited's emissions and climate commitments are crucial for aligning with global climate goals and enhancing corporate responsibility in the pharmaceutical sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Seqirus UK Limited’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Seqirus UK Limited yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from CSL Limited
Carbon Disclosure Project
Inherited from CSL Limited
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Seqirus UK Limited
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project